Sobi Highlights Pacritinib Data, Broad Portfolio at ASH 2025
Event summary
- Sobi will present 19 scientific abstracts at the ASH 2025 Annual Meeting, including two oral presentations.
- A post-hoc analysis of pacritinib data will be presented, demonstrating spleen size reduction and symptom improvement in high-risk myelofibrosis patients.
- Sobi’s portfolio data will be showcased, including efanesoctocog alfa, pegcetacoplan, avatrombopag, emapalumab, and loncastuximab tesirine.
- The meeting takes place December 6-9, 2025, in Orlando, Florida.
The big picture
Sobi's focus on rare hematological disorders positions it within a growing, albeit niche, biopharmaceutical market. The ASH presentation highlights the company's commitment to data-driven development and underscores the importance of demonstrating real-world efficacy for its portfolio of therapies. Pacritinib's accelerated approval pathway creates both opportunity and risk, demanding rigorous validation of its clinical benefits.
What we're watching
- Regulatory Approval
- The success of pacritinib’s accelerated approval hinges on confirmatory trials; failure to demonstrate clinical benefit could trigger a regulatory review.
- Commercialization
- The ongoing collaboration with Sanofi for efanesoctocog alfa will be critical for Sobi’s expansion in North America, and the terms of this partnership will dictate revenue sharing and market access.
- Pipeline Expansion
- Sobi's continued investment in rare hematology therapies, particularly those leveraging complement inhibition like pegcetacoplan, will determine its long-term competitive positioning.
Related topics